Vinge advises Biotage in connection with its acquisition of PhyNexus
Vinge advises Biotage AB (publ) (“Biotage”), listed on Nasdaq Stockholm, in connection with its acquisition of PhyNexus, Inc. (“PhyNexus”), financed through a combination of newly issued shares and existing cash at hand.
The transaction is expected to be completed in January 2019 and is subject to customary closing conditions.
Biotage offers efficient separation technologies from analysis to industrial-scale and high-quality solutions for analytical chemistry from research to commercial analysis laboratories. The company is headquartered in Uppsala and has offices in the US, UK, China, Japan, South Korea and India. Biotage has approx. 410 employees and had sales of 748 MSEK in 2017.
Vinge’s team consists of Dain Hård Nevonen, Malte Hedlund and Josephine Andersson.